-+ 0.00%
-+ 0.00%
-+ 0.00%

Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026

Benzinga·05/18/2026 20:10:50
Listen to the news

– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease –